Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Verisante Revises LOI for China Rights to Cancer Diagnostic Device

publication date: Oct 3, 2014
Verisante Technology of Canada has reworked the terms of a Letter of Intent with an unnamed partner for global/China rights to its cancer detection technology. Under the new agreement, the rights to the technology will be placed in an LLC, which will be listed as soon as possible on Shenzhen's OTC stock exchange to raise additional capital. Verisante will own 30% of the LLC. The LLC will own worldwide rights to commercialize Verisante's Core™ Raman technology and ClearVu endoscopic system to detect lung cancer and China rights to other Core products. The partner will make a $2.15 million investment in Verisante. More details....

Stock Symbols: (TSX: VRS; OTCQX: VRSEF)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here